AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
- Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)
- Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies
Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024. In addition, Andrea Pfeifer, Ph.D., CEO of AC Immune SA will lead an industry symposium exploring the latest clinical advances in the diagnosis and treatment of alpha-synuclein pathologies.
Industry Symposium: State-of-the-art of treatment and diagnosis of alpha-synuclein pathologies
Session Date/Time: March 6, 2024 at 8:40 – 10:40 am WET
Opening and Closing Remarks: Andrea Pfeifer, Ph.D., CEO of AC Immune SA
Recent developments in the diagnosis of synucleinopathies
Presenter: Werner Poewe, M.D. (Medical University of Innsbruck, Austria)
Time: 8:45 – 9:10 am WET
Development of an a-syn-PET tracer for alpha-synucleinopathies
Presenter: Francesca Capotosti, Ph.D. (AC Immune)
Time: 9:10 – 9:25 am WET
New therapeutic approaches in Parkinson's disease
Presenter: Fabrizio Stocchi, M.D., Ph.D. (University San Raffaele Roma, Italy)
Time: 9:25 – 9:45 am WET
Morphomer a-syn: small molecules targeting a-syn for the treatment of PD
Presenter: Elpida Tsika, Ph.D. (AC Immune)
Time: 9:45 – 10:05 am WET
Active immunotherapy ACI-7104.056 in early PD: update from the Phase 2 trial VacSYn
Presenter: Nuno Mendonça, M.D. (AC Immune)
Time: 10:05 – 10:20 am WET
Oral Presentations
Utility of [18F]PI-2620 PET in clinical trials: insights into tau pathology deposition in Down Syndrome
Presenter: Marija Vukicevic, Ph.D. (AC Immune)
Session: Therapeutic targets in AD: Tau proteins
Date/Time: March 8, 2024 at 8:55 – 9:10 am WET
Targeting TDP-43 with a vectorized full-length antibody decreases neuropathology in a model of ALS/FTD
Presenter: Damien Nevoltris, Ph.D. (AC Immune)
Session: FTD, ALS: TDP-43, C9ORF72 and TMEM106B 02
Date/Time: March 8, 2024 at 2:05 – 2:20 pm WET
Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43 PET tracer
Presenter: Tamara Seredenina, Ph.D. (AC Immune)
Session: FTD, ALS: TDP-43, C9ORF72 and TMEM106B 02
Date/Time: March 8, 2024 at 2:20 – 2:35 pm WET
VacSYn study: An innovative biomarker-based phase 2 clinical trial to evaluate ACI-7104.056, a novel active immunotherapy for Parkinson’s disease
Presenter: Dymitr Kostrica, M.D. (AC Immune)
Session: Advances in PD and LBD drug development
Date/Time: March 9, 2024 at 5:25 – 5:40 pm WET
Poster Presentations
Anti-Abeta liposomal vaccine, ACI-24.060, retains memory in aggressive mouse model of Alzheimer’s disease
Poster number: P0215 / #1422
Presenter: Emma Fiorini, Ph.D. (AC Immune)
Discovery and optimization of novel potent brain penetrant NLRP3 inhibitors
Poster number: P0114 / #1470
Presenter: Tamara Seredenina, Ph.D. (AC Immune)
ACI-7104.056, an active immunotherapy for synucleinopathies, induces a strong and sustained antibody response against alpha-synuclein in non-human primates
Poster number: P0996 / #1513
Presenter: Guenther Staffler, Ph.D. (AC Immune)
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding in potential milestone payments plus royalties.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | U.S. Investors Corey Davis, Ph.D. LifeSci Advisors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments, and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
